雌激素受体拮抗剂对泌乳素腺瘤GH3细胞增殖的影响(5)
[16] Faraoni E Y,Camilletti M A,Abeledo-Machado A,et al.
Sex differences in the development of prolactinoma in mice overexpressing hCGβ:role of TGFβ1[J].Journal of Endocrinology,2017,232(3):535-546.
[17] Hajder M,Hajder E,Dervisefendic M,et al.Prolactinomas in infertile women:clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine[J].Medical Archives,2013,67(3):181-184.
[18] Filopanti M,Barbieri A M,Angioni A R,et al.Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas[J].Pharmacogenomics Journal,2008,8(5):357-363.
[19] Wu Z B,Zheng W M,Su Z P,et al.Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas:correlation with the response to bromocriptine and with tumor biological behavior[J].J Neurooncol,2010,99(1):25-32.
[20] Shimazu S,Shimatsu A,Yamada S,et al.Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels[J].European Journal of Endocrinology,2012,166(3):383-390.
[21] Cao L,Gao H,Gui S,et al.Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models[J].
J Neurooncol,2014,116(3):523-531.
(收稿日期:2018-09-28) (本文編辑:周亚杰), 百拇医药(朱正凯 林少华 李亮明)
Sex differences in the development of prolactinoma in mice overexpressing hCGβ:role of TGFβ1[J].Journal of Endocrinology,2017,232(3):535-546.
[17] Hajder M,Hajder E,Dervisefendic M,et al.Prolactinomas in infertile women:clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine[J].Medical Archives,2013,67(3):181-184.
[18] Filopanti M,Barbieri A M,Angioni A R,et al.Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas[J].Pharmacogenomics Journal,2008,8(5):357-363.
[19] Wu Z B,Zheng W M,Su Z P,et al.Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas:correlation with the response to bromocriptine and with tumor biological behavior[J].J Neurooncol,2010,99(1):25-32.
[20] Shimazu S,Shimatsu A,Yamada S,et al.Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels[J].European Journal of Endocrinology,2012,166(3):383-390.
[21] Cao L,Gao H,Gui S,et al.Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models[J].
J Neurooncol,2014,116(3):523-531.
(收稿日期:2018-09-28) (本文編辑:周亚杰), 百拇医药(朱正凯 林少华 李亮明)